Phio Presents PH-762 Phase 1b Data at SITC
Phio Pharmaceuticals will share Phase 1b clinical results for its INTASYL PH-762 treatment at the 41st SITC Annual Meeting in Phoenix, Arizona.
Updated on Nov. 6, 2026 in Cancer
Phio Pharmaceuticals Corp. will present clinical data from its Phase 1b trial of INTASYL PH-762 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, held November 6-8, 2026, in Phoenix, Arizona. The data concern a neoadjuvant intratumoral injection designed to silence the PD-1 gene in cutaneous carcinomas.
Why it matters
The trial evaluated PH-762 for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma, and the company says it may offer a new option capable of shrinking tumors before surgery. Current cSCC standards rely on Mohs micrographic surgery and/or standard excision.
The presentation draws on Phase 1b trial NCT06014086, which tested PH-762 across cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. Results are compared against current cSCC treatments of Mohs micrographic surgery and/or standard excision, but the specific efficacy and safety figures were not disclosed in the source.
The players
Phio Pharmaceuticals Corp.
A clinical-stage siRNA biopharmaceutical company developing gene-silencing therapies for cancer, trading on NASDAQ under the ticker PHIO.
John Strasswimmer, M.D., Ph.D.
The lead investigator for the Phase 1b trial of PH-762, whose practice is based in Delray Beach, Florida.
Society for Immunotherapy of Cancer
The professional organization that hosts the annual SITC meeting, a major forum for cancer immunotherapy research.
The details
Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company traded on NASDAQ under PHIO, will present the data through lead investigator John Strasswimmer, M.D., Ph.D. INTASYL uses siRNA gene silencing technology to enhance the body's immune cells against cancer cells.
Timeline
November 6-8, 2026: 41st SITC Annual Meeting in Phoenix, Arizona
First half of 2027: Planned Phase 2b study of PH-762
Big Picture
Presenting Phase 1b results at SITC follows the established pattern of early-stage immunotherapy trials reporting data at the meeting before advancing to later phases. The planned Phase 2b study for PH-762 would extend that pathway for a topically or intratumorally delivered siRNA treatment.
PH-762 may give patients with cutaneous carcinomas a tissue-sparing option that shrinks tumors before surgery. Any eventual availability would depend on the outcome of later-phase trials, which have not yet begun.
The takeaway
Patients considering treatment for skin cancers can ask their physicians whether neoadjuvant options or clinical trials are appropriate for their diagnosis. Early-stage results like these inform, but do not replace, established surgical care.
What happens next
A Phase 2b study of PH-762 is planned for the first half of 2027.
Further reading
Explore more Cancer coverage to see how immunotherapy research is advancing across the United States.
